Literature DB >> 25835179

Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer.

Mosin S Khan1, Arshad A Pandith2, Shariq R Masoodi3,4, Shoukat H Khan5, Tanveer A Rather5, Khursid I Andrabi6, Syed Mudassar1.   

Abstract

BACKGROUND: Among various polymorphic variants of TP53 gene, codon 72 polymorphism (Arg72Pro) has been found to be associated with cancer susceptibility, but only few studies have investigated their effect on thyroid cancer risk.
OBJECTIVE: A case control study was conducted to elucidate the possible role of this SNP as risk factor in thyroid cancer development and to examine its correlation with various clinicopathological variables.
METHODS: In this study, we tested the genotype distribution by PCR-RFLP in 140 thyroid cancer patients and 200 cancer-free controls from Kashmir Valley.
RESULTS: Genotype frequencies of Arg/Arg (GG), Arg/Pro (GC), and Pro/Pro (CC) genotypes among cases were 0.286, 0.343 and 0.371 while in controls 0.45, 0.37 and 0.18 respectively. Proline allele frequency was significantly higher than arginine frequency in patient group (OR = 2.06, 95% C.I = 1.5-2.8). Significant association was found between variant genotype of codon 72 of TP53 gene and young age group, female gender, urban dwellers, non-smokers and patients with elevated TSH levels (P < 0.05).
CONCLUSION: It is evident from our study that Arg72Pro SNP of TP53 gene is connected with higher susceptibility to thyroid cancer especially in young age group, female gender, non-smokers and patients with elevated TSH levels, hence, implicated in thyroid carcinogenesis.

Entities:  

Keywords:  Papillary thyroid cancer; benign thyroid disease; differentiated thyroid cancer; polymerase chain reaction; restriction digestion; thyroid stimulating hormone

Mesh:

Substances:

Year:  2015        PMID: 25835179     DOI: 10.3233/CBM-150485

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

1.  The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

Authors:  Jing He; Fenghua Wang; Jinhong Zhu; Zhuorong Zhang; Yan Zou; Ruizhong Zhang; Tianyou Yang; Huimin Xia
Journal:  Aging (Albany NY)       Date:  2017-03-08       Impact factor: 5.682

2.  TP53 Arg72Pro polymorphism and neuroblastoma susceptibility in eastern Chinese children: a three-center case-control study.

Authors:  Yuan Fang; Xuemei Wu; Lin Li; Jinhong Zhu; Haiyan Wu; Haixia Zhou; Jing He; Yizhen Wang
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

3.  TP53 rs1042522 C>G polymorphism and Wilms tumor susceptibility in Chinese children: a four-center case-control study.

Authors:  Peng Liu; Zhenjian Zhuo; Wenya Li; Jiwen Cheng; Haixia Zhou; Jing He; Jiao Zhang; Jiaxiang Wang
Journal:  Biosci Rep       Date:  2019-01-22       Impact factor: 3.840

4.  Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population.

Authors:  Mikhlid H Almutairi; Bader O Almutairi; Turki M Alrubie; Sultan N Alharbi; Narasimha R Parine; Abdulwahed F Alrefaei; Ibrahim Aldeailej; Abdullah Alamri; Abdelhabib Semlali
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

5.  Combining Network Pharmacology with Molecular Docking for Mechanistic Research on Thyroid Dysfunction Caused by Polybrominated Diphenyl Ethers and Their Metabolites.

Authors:  Qiaoyu He; Xiaopeng Chen; Jing Liu; Chunxia Li; Hong Xing; Yumeng Shi; Qian Tang
Journal:  Biomed Res Int       Date:  2021-11-17       Impact factor: 3.411

6.  Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children.

Authors:  Fan Liao; Li Yuan; Jinhong Zhu; Wei Chen; Yemu Zhao; Jing He
Journal:  Biomed Res Int       Date:  2022-08-13       Impact factor: 3.246

7.  Association among Body Mass Index, Genetic Variants of FTO, and Thyroid Cancer Risk: A Hospital-Based Case-Control Study of the Cancer Screenee Cohort in Korea.

Authors:  Tung Hoang; Dayoung Song; Jeonghee Lee; Eun Kyung Lee; Yul Hwangbo; Jeongseon Kim
Journal:  Cancer Res Treat       Date:  2020-12-07       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.